ArticleMolecular biology reports2025
Investigating the expression of CD180, LY96, VCAM-1, and CSF2RB in the lipopolysaccharide response pathway across different liver cirrhosis etiologies.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLiver cirrhosis represents a significant global health burden with diverse etiological factors. The lipopolysaccharide response pathway is critical in liver disease development. This study investigates this pathway in liver cirrhosis associated with various etiologies, including nonalcoholic steatohepatitis, alcohol consumption, viral infections, autoimmune disorders, and cholestatic disorders. METHODS AND
resultsThe GSE25097 and GSE54238 microarray datasets were retrieved from the Gene Expression Omnibus (GEO) database using R software. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed on the overlapping Differentially Expressed Genes (DEGs). Gene expression was determined by RT-qPCR, and protein expression was determined by Western blot. A total of 499 overlapping DEGs were identified between the two datasets. Then, the GOBP enrichment analysis subsequently discovered the lipopolysaccharide response pathway, highlighting genes such as CD180, LY96, VCAM-1, and CSF2RB. Based on bioinformatics analysis, the expressions of all mentioned genes were elevated in cirrhotic samples. However, experimental results showed an increase only in CD180 gene expression. Our research has shown that the expressions of the LY96, VCAM-1, and CSF2RB genes were elevated only in PSC cirrhosis. The PSC group had an elevation in LY96 protein expression. On the other hand, all the gene expressions significantly decreased in NASH cirrhosis, although only the VCAM-1 protein expression was reduced in NASH cirrhosis.
conclusionsThe response to the lipopolysaccharide pathway has a complicated role in liver disease pathogenesis. While gene expression of pathway components increases in cholangitis-related cirrhosis, it decreases in NASH-associated cirrhosis.
Indexed as
Identifiers
40586795What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.